WALTHAM, Mass.--(EON: Enhanced Online News)--NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) reported increased media attention on the company’s Quell® Wearable Pain Relief Technology™, including an in depth report on CBS’s Innovation Nation. Highlights include:
“We are excited about the continued high level of attention Quell is gaining among consumer, technology and healthcare media. “”
CBS Innovation Nation - The Medicine-Free Pain Relieving Device
MedCity News – Arianna Huffington Takes on Consumer Wellness
Pain News Network – Quell Relieves Back Pain Without Medication
National Pain Report – My Favorite Tool for Reducing Fibromyalgia
Fibromyalgia News Today – NeuroMetrix to Test Quell Pain Relief Device in Fibromyalgia Pilot
Sleep Review Magazine – NeuroMetrix Health Cloud Collects 1 Million Hours Therapy Health Data
“Chronic pain sufferers are desperate for more effective tools to manage their condition, and Quell’s 100% drug-free pain relief is resonating,” said Frank McGillin, Senior Vice President and Chief Commercial Officer NeuroMetrix. “We are excited about the continued high level of attention Quell is gaining among consumer, technology and healthcare media. “
Quell is designed for millions of people suffering from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell users can start, stop, and adjust therapy discreetly via the optional Quell Relief app. Quell also offers advanced sleep tracking that provides feedback on eight dimensions of sleep including sleep duration, quality, body position, time out of bed, and repetitive leg movements throughout the night. Quell was the winner of the 2016 SXSW (South by Southwest) Innovation Award for Best Wearable Technology. Quell is available at select healthcare professionals and retailers. Visit QuellRelief.com for more information.
NeuroMetrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs, including a therapeutic device for restless leg syndrome. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.